Edmond DE Rothschild Holding S.A. Sells 13,747 Shares of Edwards Lifesciences Co. (NYSE:EW)

Edmond DE Rothschild Holding S.A. reduced its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 645,587 shares of the medical research company's stock after selling 13,747 shares during the period. Edwards Lifesciences makes up 0.8% of Edmond DE Rothschild Holding S.A.'s portfolio, making the stock its 28th biggest position. Edmond DE Rothschild Holding S.A. owned approximately 0.11% of Edwards Lifesciences worth $47,793,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of EW. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth approximately $29,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $30,000. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth $46,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on EW shares. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $79.95.

Remove Ads

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.22 during mid-day trading on Wednesday, reaching $72.09. 2,864,353 shares of the company's stock traded hands, compared to its average volume of 4,800,358. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The company has a market cap of $42.38 billion, a price-to-earnings ratio of 10.34, a PEG ratio of 4.82 and a beta of 1.15. The stock has a 50 day moving average of $71.59 and a two-hundred day moving average of $70.59. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,553 shares of company stock worth $4,513,064. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.